Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 870 participants.

Also called NCT07135089

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 870 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07135089
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07135089. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-13 (actual); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Improving Neuroprotective Strategy for Ischemic Stroke Before Endovascular Thrombectomy by Intravenous Tirofiban
Acronym
INSIST-IT2
Condition
Stroke, Ischemic
Intervention (Drug)
Intravenous tirofiban before endovascular thrombectomy
Intervention (Drug)
Intravenous placebo before endovascular thrombectomy
Lead sponsor
General Hospital of Shenyang Military Region (class: other)

Record details

Record id
cardio:ct-nct07135089
Content hash
2e688df041b312e883ebef74de045e740208aa5a7f03e0b7efb0874bc047d328